Farmers Trust Co. Has $241,000 Stake in Eli Lilly and Company (NYSE:LLY)

Farmers Trust Co. lifted its position in shares of Eli Lilly and Company (NYSE:LLYFree Report) by 10.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 414 shares of the company’s stock after purchasing an additional 38 shares during the period. Farmers Trust Co.’s holdings in Eli Lilly and Company were worth $241,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. Thompson Investment Management Inc. acquired a new position in shares of Eli Lilly and Company during the 3rd quarter worth approximately $27,000. Retirement Group LLC raised its position in shares of Eli Lilly and Company by 159.1% in the second quarter. Retirement Group LLC now owns 57 shares of the company’s stock valued at $27,000 after purchasing an additional 35 shares during the period. Cornerstone Planning Group LLC bought a new position in shares of Eli Lilly and Company in the second quarter valued at about $33,000. Legacy Financial Group LLC bought a new position in shares of Eli Lilly and Company in the third quarter valued at about $35,000. Finally, Optiver Holding B.V. bought a new position in Eli Lilly and Company in the 3rd quarter valued at about $36,000. 81.38% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Down 0.9 %

Shares of LLY stock opened at $754.17 on Friday. The stock’s fifty day simple moving average is $708.78 and its 200 day simple moving average is $625.25. Eli Lilly and Company has a twelve month low of $323.26 and a twelve month high of $800.78. The firm has a market capitalization of $716.59 billion, a P/E ratio of 130.03, a P/E/G ratio of 1.66 and a beta of 0.34. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69.

Eli Lilly and Company (NYSE:LLYGet Free Report) last announced its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. During the same period last year, the company earned $2.09 EPS. Eli Lilly and Company’s revenue for the quarter was up 28.1% compared to the same quarter last year. As a group, sell-side analysts predict that Eli Lilly and Company will post 12.41 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Morgan Stanley upped their target price on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research report on Friday, February 16th. Barclays upped their price objective on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a report on Wednesday, February 7th. BMO Capital Markets upped their price objective on Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a report on Wednesday, February 7th. Truist Financial upped their price target on shares of Eli Lilly and Company from $650.00 to $850.00 and gave the company a “buy” rating in a research note on Wednesday, February 7th. Finally, DZ Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price on the stock. in a research report on Wednesday, February 21st. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $677.62.

View Our Latest Research Report on Eli Lilly and Company

Insider Activity at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the company’s stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the transaction, the insider now directly owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 195,055 shares of company stock worth $125,254,657 in the last quarter. Company insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Further Reading

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.